RATIONALE: Zolpidem is a hypnotic drug that binds to γ-aminobutyric acid type A receptors but lacks consistently demonstrable anxiolytic efficacy. METHODS: Rhesus monkeys (N = 4) were trained under a multiple schedule in which food-maintained responding was programmed (18-response fixed ratio) for a 5-min period, followed by a 5-min period in which the food-maintained responding was suppressed by response-contingent electric shock (20-response fixed ratio). Doses of zolpidem (range = 0.03 to 1.0 mg/kg, i.v.) were administered 5 min before the session, and responding was re-assessed at three additional 20-min intervals. A similar experiment also was carried out with the non-selective benzodiazepine, triazolam, over a dose range of 0.001 to 0.1 mg/kg, i.v. RESULTS: Zolpidem did not engender a significant increase in average rates of suppressed responding at earlier time points; however, rates of non-suppressed responding were robustly decreased. At 45- and 65-min post-injection, zolpidem treatment resulted in a dose-dependent increase in rates of suppressed responding. In contrast, the non-selective benzodiazepine triazolam increased rates of suppressed responding in a dose-dependent manner at all four time points, although decreases in non-suppressed responding were less at the later time points. CONCLUSIONS: These findings suggest that zolpidem has anxiolytic-like effects, but only >25 min after i.v. injection in this rhesus monkey conflict model. It was hypothesized that time-dependent effects on the response rate-suppressing properties of zolpidem become tolerant (i.e., acute tolerance). Because anxiolytic-like effects remain stable throughout the session, the absence of rate-decreasing effects may "unmask" anti-conflict effects.
RATIONALE: Zolpidem is a hypnotic drug that binds to γ-aminobutyric acid type A receptors but lacks consistently demonstrable anxiolytic efficacy. METHODS:Rhesus monkeys (N = 4) were trained under a multiple schedule in which food-maintained responding was programmed (18-response fixed ratio) for a 5-min period, followed by a 5-min period in which the food-maintained responding was suppressed by response-contingent electric shock (20-response fixed ratio). Doses of zolpidem (range = 0.03 to 1.0 mg/kg, i.v.) were administered 5 min before the session, and responding was re-assessed at three additional 20-min intervals. A similar experiment also was carried out with the non-selective benzodiazepine, triazolam, over a dose range of 0.001 to 0.1 mg/kg, i.v. RESULTS:Zolpidem did not engender a significant increase in average rates of suppressed responding at earlier time points; however, rates of non-suppressed responding were robustly decreased. At 45- and 65-min post-injection, zolpidem treatment resulted in a dose-dependent increase in rates of suppressed responding. In contrast, the non-selective benzodiazepinetriazolam increased rates of suppressed responding in a dose-dependent manner at all four time points, although decreases in non-suppressed responding were less at the later time points. CONCLUSIONS: These findings suggest that zolpidem has anxiolytic-like effects, but only >25 min after i.v. injection in this rhesus monkey conflict model. It was hypothesized that time-dependent effects on the response rate-suppressing properties of zolpidem become tolerant (i.e., acute tolerance). Because anxiolytic-like effects remain stable throughout the session, the absence of rate-decreasing effects may "unmask" anti-conflict effects.
Authors: Donna M Platt; James K Rowlett; Roger D Spealman; James Cook; Chunrong Ma Journal: Psychopharmacology (Berl) Date: 2002-09-04 Impact factor: 4.530
Authors: R M McKernan; T W Rosahl; D S Reynolds; C Sur; K A Wafford; J R Atack; S Farrar; J Myers; G Cook; P Ferris; L Garrett; L Bristow; G Marshall; A Macaulay; N Brown; O Howell; K W Moore; R W Carling; L J Street; J L Castro; C I Ragan; G R Dawson; P J Whiting Journal: Nat Neurosci Date: 2000-06 Impact factor: 24.884
Authors: S L de Haas; R C Schoemaker; J M A van Gerven; P Hoever; A F Cohen; J Dingemanse Journal: J Psychopharmacol Date: 2009-07-31 Impact factor: 4.153
Authors: Harald Ihmsen; Sven Albrecht; Werner Hering; Jürgen Schüttler; Helmut Schwilden Journal: Br J Clin Pharmacol Date: 2004-02 Impact factor: 4.335
Authors: Eileen K Sawyer; Casey Moran; Madelynn H Sirbu; Melissa Szafir; Michael Van Linn; Ojas Namjoshi; V V N Phani Babu Tiruveedhula; James M Cook; Donna M Platt Journal: Alcohol Clin Exp Res Date: 2013-12-13 Impact factor: 3.455